Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid

Luciani-Giacobbe, Laura Carolina; Lorenzutti, Augusto Matías; Litterio, Nicolás Javier; Ramírez-Rigo, María Verónica; Olivera, Marı́a Eugenia

doi:10.1007/s13346-020-00847-9

Cited by 9 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different from usual acute bacterial infection, infection with mycobacterium tuberculosis is a chronic reaction generating no endotoxin, exotoxin, invasive enzyme, flagellum and spores, with lipid as its chief pathogenic substance. Additionally, novel delivery system of anti-tuberculosis drugs to improve their bioavailability is a research focus currently [ 31 ], while in situ administration reduces isonicotinic acid hydrazide and rifampicin acid interaction in the stomach so as to avoid inadequate RIF bioavailability and drug resistant tuberculosis [ 32 ]. The above factors might explain why tuberculous TAP patients are ideal candidates for TEVAR with adjunctive procedure.…”

Section: Discussionmentioning

confidence: 99%

Zone 2/3 lesion and emergency repair as potential mortality predictors of TEVAR for thoracic aortic pseudoaneurysm

Wang,

Shu,

Wang

et al. 2023

J Cardiothorac Surg

View full text Add to dashboard Cite

Objective Thoracic aortic pseudoaneurysm (TAP) is an uncommon but life-threatening condition. The present study aimed to investigate the early and midterm clinical outcome of TAP patients following TEVAR and identify potential mortality predictors. Methods We retrospectively reviewed a series of 37 eligible patients with TAP admitted to our hospital from July 2010 to July 2020. We explored their baseline, perioperative and follow-up data. Fisher exact test and Kaplan–Meier method were applied for comparing difference between groups. Results There were 29 men and 12 women, with the mean age as 59.5 ± 13.0 years (range 30–82). The mean follow-up period was 30.7 ± 28.3 months (range 1–89). For early outcome (≤ 30 days), mortality happened in 3 (8.1%) zone 3 TAP patients versus 0 in zone 4 (p = 0.028); postoperative acute arterial embolism of lower extremity and type II endoleak respectively occurred in 1(2.7%) case. For midterm outcome, survival at 3 months, 1 year and 5 years was 88.8%, 75.9% and 68.3%, which showed significant difference between zone 2/3 versus zone 4 group (56.3% vs. 72.9%, p = 0.013) and emergent versus elective TEVAR group (0.0% versus 80.1%, p = 0.049). Previous stent grafting or esophageal foreign body with Aortoesophageal fistula (AEF), and systemic vasculitis, as etiologies, resulted in encouraging immediate outcome but worse midterm prognosis. Conclusion TAP lesions at zone 2/3 and emergent TEVAR predict worse midterm outcomes compared to zone 4 lesions and elective TEVAR. The outcomes are also mainly restricted by the etiology of the TAP.

show abstract

Section: Discussionmentioning

confidence: 99%

Zone 2/3 lesion and emergency repair as potential mortality predictors of TEVAR for thoracic aortic pseudoaneurysm

Wang,

Shu,

Wang

et al. 2023

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

“…Because one drug can be enteric coated to release in the stomach and the other in the ileum, floating delivery systems are useful for ATD fixed-dose combos. Studies have shown that more RIF is absorbed from the stomach even in the presence of INH [196].…”

Section: Polymeric-microparticulate Drug Delivery Systemsmentioning

confidence: 99%

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

Nair,

Greeny,

Nandan

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Tuberculosis (TB) remains a significant global health challenge, necessitating innovative approaches for effective treatment. Conventional TB therapy encounters several limitations, including extended treatment duration, drug resistance, patient noncompliance, poor bioavailability, and suboptimal targeting. Advanced drug delivery strategies have emerged as a promising approach to address these challenges. They have the potential to enhance therapeutic outcomes and improve TB patient compliance by providing benefits such as multiple drug encapsulation, sustained release, targeted delivery, reduced dosing frequency, and minimal side effects. This review examines the current landscape of drug delivery strategies for effective TB management, specifically highlighting lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, emulsion-based systems, carbon nanotubes, graphene, and hydrogels as promising approaches. Furthermore, emerging therapeutic strategies like targeted therapy, long-acting therapeutics, extrapulmonary therapy, phototherapy, and immunotherapy are emphasized. The review also discusses the future trajectory and challenges of developing drug delivery systems for TB. In conclusion, nanomedicine has made substantial progress in addressing the challenges posed by conventional TB drugs. Moreover, by harnessing the unique targeting abilities, extended duration of action, and specificity of advanced therapeutics, innovative solutions are offered that have the potential to revolutionize TB therapy, thereby enhancing treatment outcomes and patient compliance. Graphical Abstract

show abstract

“…The model drugs chosen for this test were reflective of many pharmaceuticals in the US pharmacopeia while providing a range of molecular weights, hydrophobicity, solubilities, and charges (Table 3). Some compounds are also in use medically already; rifampin has historically been used to treat tuberculosis [49] and has more recently been used to treat atopic dermatitis [50]. Rifampin and crystal violet also show anti-fungal and anti-bacterial activity in several studies [51,52].…”

Section: Drug Release Testingmentioning

confidence: 99%

Air-Spun Silk-Based Micro-/Nanofibers and Thin Films for Drug Delivery

Gough

2021

IJMS

View full text Add to dashboard Cite

Micro-/nanofibers have shown high promise as drug delivery vehicles due to their high porosity and surface-area-to-volume ratio. The current study utilizes air-spraying, a novel fiber fabrication technique, to create silk micro-/nanofibers without the need for a high voltage power source. Air-spraying was used to create silk fibrous mats embedded with several model drugs with high efficiency. In order to compare the effect of biomaterial geometry on the release of the model drugs, silk films were also created and characterized. Fourier-transform infrared spectroscopy (FTIR), scanning electron microscope (SEM), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and a drug release study were performed on both fiber and film samples to study how the model drugs interact with the protein structure. FTIR analysis showed that while drugs could interact with the protein structure of porous silk fibers, they could not interact with the flat geometry of silk films. As a result, fibers could protect select model drugs from thermal degradation and slow their release from the fiber network with more control than the silk films. A trend was also revealed where hydrophobic drugs were better protected and had a slower release than hydrophilic drugs. The results suggest that the physical and chemical properties of drugs and protein-based biomaterials are important for creating drug delivery vehicles with tailored release profiles and that fibers provide better tunability than films do.

show abstract

Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid

Cited by 9 publications

References 32 publications

Zone 2/3 lesion and emergency repair as potential mortality predictors of TEVAR for thoracic aortic pseudoaneurysm

Zone 2/3 lesion and emergency repair as potential mortality predictors of TEVAR for thoracic aortic pseudoaneurysm

Advanced drug delivery and therapeutic strategies for tuberculosis treatment

Air-Spun Silk-Based Micro-/Nanofibers and Thin Films for Drug Delivery

Contact Info

Product

Resources

About